赛诺医疗公告称，2025年预计营收5.19亿元至5.26亿元，同比增长13%至15%；预计归属于上市公司股 东的净利润4300万元至5000万元，同比增长2767%至3233%；扣非净利润3000万元至3580万元，实现扭 亏为盈。营收增长主因冠脉介入业务和神经介入业务收入增加；净利润大幅增长受营收增长、成本费用 变动及上年基数小等因素影响。 ...

山外山公告称，预计2025年年度归属于母公司所有者的净利润为14,035.49万元到15,949.42万元，同比增 加98%到125%；扣非净利润为13,436.81万元到15,438.03万元，同比增加135%到170%。上年同期净利润 为7,088.63万元，扣非净利润为5,717.79万元。业绩增长因产品市场占有率提升、耗材销售收入大幅增加 及毛利率提升。本次业绩预告未经审计，具体数据以年报为准。 ...

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of the parent company between 140 million to 159 million yuan in 2025, representing an increase of 69.4686 million to 88.6079 million yuan compared to the previous year, which is a year-on-year increase of 98% to 125% [1] Financial Performance - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between 134 million to 154 million yuan, with an increase of 77.1902 million to 97.2024 million yuan compared to the previous year, indicating a year-on-year growth of 135% to 170% [1] Market Position - The company is a leading domestic player in blood purification equipment, leveraging its technological advantages and strong brand effect to continuously increase its market share [1] - The sales revenue of the company's self-produced blood purification consumables has significantly increased during the reporting period [1]

公司作为国产血液净化设备的龙头企业，依托技术领先优势和强大的品牌效应，产品市场占有率持续提 升，推动了血液净化设备销售收入的稳步增长。 格隆汇1月30日丨山外山(688410.SH)公布，经财务部门初步测算，预计2025年年度实现归属于母公司所 有者的净利润为14,035.49万元到15,949.42万元，同比增加98%到125%。归属于母公司所有者的扣除非 经常性损益的净利润为13,436.81万元到15,438.03万元，同比增加135%到170%。 ...

归属于母公司所有者的扣除非经常性损益的净利润为1.34亿元到1.54亿元，与上年同期(法定披露数据) 相比，将增加7719.02万元到9720.24万元，同比增加135%到170%。 本期业绩变化的主要原因：(一)公司作为国产血液净化设备的龙头企业，依托技术领先优势和强大的品 牌效应，产品市场占有率持续提升，推动了血液净化设备销售收入的稳步增长；(二)报告期内公司自产 的血液净化耗材销售收入大幅提升；(三)随着产销量的提升，自产耗材单位固定成本进一步下降，毛利 率提升，公司总体盈利能力进一步加强。 格隆汇1月30日丨山外山(688410.SH)公布，经公司财务部门初步测算，预计2025年年度实现归属于母公 司所有者的净利润为1.40亿元到1.59亿元，与上年同期(法定披露数据)相比，将增加6946.86万元到 8860.79万元，同比增加98%到125%。 ...

Core Viewpoint - The company anticipates a significant decline in net profit for the fiscal year 2025, projecting a loss between 52 million to 42 million yuan, representing a year-on-year decrease of 344.23% to 297.26% [1] Financial Performance - The expected non-recurring net profit is projected to be between -72 million to -62 million yuan, indicating a year-on-year decrease of 605.13% to 534.97% [1] - The decline in revenue and gross profit from the HPV product line is estimated to be approximately 46.5 million yuan and 46 million yuan, respectively [1] Operational Factors - The decrease in financial performance is attributed to the national centralized procurement policy affecting the HPV product line [1] - Business structure optimization and channel strategy adjustments have negatively impacted the current gross profit [1] - Increased research and development investments have led to a rise in costs [1] - The company has made provisions for asset impairment [1] Non-Recurring Gains - There has been an increase in investment income from associated companies, contributing positively to non-recurring gains [1]

格隆汇1月30日｜赛诺医疗公告称，预计2025年归属于上市公司股东的净利润为4300万元至5000万元， 较上年同期增加4150万元至4850万元，同比增长2767%至3233%。主要因冠脉及神经介入业务收入增 长、营业成本和管理费用小幅增长、销售费用及研发费用下降、资产减值损失大幅减少，叠加上年同期 净利润基数较小。 ...

截至午间收盘 该指数涨跌 -0. 6% 该指数 滚动市盈率 174. 4倍 1月30日早盘，科创板下探后持续反弹，截至午间收盘。科创200指数、科创成长指数均上涨0.1%，科创宗指下跌0.5%，科创50指数下跌0.6%，科创100指数 下跌0.9%。 Wind数据显示，科创50ETF易方达（588080）连续2个交易日获净流入，合计5.7亿元。 科创板系列指数基本情况跟踪 (2026年1月30日) 科创50ETF易方达 低费率 跟踪上证科创板50成份指数 该指数由科创板中市值大、流动性 好的50只股票组成,"硬科技"龙 头特征显著,半导体占比超65%, 与医疗器械、软件开发、光伏设备 行业合计占比近80% 科创100ETF易方达 FF-5-33 跟踪上证科创板100指数 该指数由科创板中市值中等且流动 性较好的100只股票组成,聚焦中 小科创企业,电子、电力设备、医 药生物、计算机行业合计占比超 75%,其中电子、电力设备行业占 比较高 截至午间收盘 该指数涨跌 该指数 滚动市盈率 -0. 9% 219.0倍 科创200ETF易方达 FF = 跟踪上证科创板综合指数 该指数由科创板全市场证券组成, 全面覆盖大 ...

Core Viewpoint - Tianyi Medical's subsidiary, Ningbo Tianyi Pharmaceutical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for blood dialysis concentrates, aimed at treating patients with acute and chronic renal failure [1] Product Registration - The registered product is intended for use in blood dialysis treatment for patients suffering from acute and chronic renal failure [1] - The actual sales performance of the registered product will depend on future market promotion efforts [1] Financial Impact - The company is currently unable to predict the impact of this product on future operating revenue [1]

Core Viewpoint - Tianyi Medical (301097.SZ) has received a Medical Device Registration Certificate from the National Medical Products Administration for its blood dialysis concentrate products, indicating a significant advancement in its product offerings in the blood purification sector [1]. Product Details - The blood dialysis concentrate consists of two components: A liquid (A液) and a dry powder (B粉). A liquid includes sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, and dialysis water, while B powder contains sodium bicarbonate [1]. - A liquid models are TR-YA3-01 and TR-YA3-02, with specifications of 5L and 10L per barrel, respectively. The B powder model is TR-FB-LBT1, with a specification of 650g per can [1]. Innovation and Market Impact - The innovative combination of A liquid and B powder offers the stability of liquid concentrates and the flexibility of dry powder formulations, allowing for more precise customization to meet clinical needs for dialysis products [1]. - The approval of this product expands the company's coverage in the blood purification field, showcasing its technological accumulation and rigorous quality management system [1]. - This development marks a deeper entry into the high-value core consumables of the medical device sector, enriching the overall solutions offered in blood purification and enhancing customer recognition and market synergy [1]. - The product's approval is expected to solidify and expand the company's leading position in the blood purification field, further improving its competitive advantage in the market [1].